Abstract:Background: BRCA 1/2 mutations are closely related to high lifetime risk of breast cancer (BC). The objective of this study was to identify the genes, regulators, and immune-associated patterns underlying disease pathology in BC with BRCA1/2 somatic mutations and their associations with clinical traits. Methods: RNA sequencing data and clinical information from The Cancer Genome Atlas (TCGA; N = 36 BRCA1 -mutant BC; N = 49 BRCA2 -mutant BC; and N = 117 BRCA1/2 -wild-type BC samples) were used for discovery, which included consensus network analysis, function enrichment, and analysis of hub genes; other TCGA data ( N = 117 triple-negative BC) and two Gene Expression Omnibus database expression profiles were used as validation cohorts. Results: Consensus network analysis helped to identify specific co-expressed modules that showed positive correlations with tumor stage, number of positive lymph nodes, and margin status in BRCA1/2 -mutant BC but lacking correlations in BRCA1/2 -wild-type BC. Functional enrichment suggested potential mechanisms in BRCA1/2 carriers that could regulate the cell cycle, immune response, cellular metabolic processes, and cell migration, via enriched pathways including p53 and JAK–STAT signaling. Consensus network analysis identified the specific and common carcinogenic mechanisms involving BRCA mutations. Regulators cross-linking these modules include E2F or IRF transcription factor family, associated with cell cycle or immune response regulation module, respectively. Eight hub genes, including ISG15 , BUB1 , and TTK , were upregulated in several BRCA1/2 -mutant BC datasets and showed prognostic value in BC. Furthermore, their genetic expression was related to higher levels of immune infiltration in BRCA1/2 -mutant BC, which manifested as recruitment of T helper cells (Th1 cells), follicular helper T cells, and regulatory T cells, and T cell exhaustion. Moreover, important indicators for evaluation of BC immunotherapy, tumor mutational burden and neoantigen load also positively correlated with expression of some hub genes. Conclusion: We constructed a BRCA1/2 mutation-type-specific co-expressed gene network with related transcription factors and immune-associated patterns that could regulate and influence tumor metastasis and immune microenvironment, providing novel insights into the pathological process of this disease and the corresponding BRCA mutations.

BRCA2 gene mutation in cancer.

BRCA1/2 associated hereditary breast cancer

BRCA1 and BRCA2 in Breast Cancer Predisposition and Recombination Control

BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies

Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management

BRCA mutations in the manifestation and treatment of ovarian cancer.

Guardians of the Genome: BRCA2 and Its Partners

BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance

Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.

BRCA1/2 Serves as a Biomarker for Poor Prognosis in Breast Carcinoma

Targeting BRCA‐mutant Biliary Tract Cancer: Current Evidence and Future Perspectives

Molecular Functions of BRCA1 in the DNA Damage Response

Brca2 Mutation Should Be Screened Routinely And Early As A Poor Prognostic Biomarker In Prostate Cancer Patients With A Family History Of Cancer

P1.03-27 Somatic Mutations in BRCA2 Genes Are Associated with Prognosis in Chinese Non-Small-Cell Lung Cancer Patients

Brca1 And Brca2 Mutations In Ovarian Cancer Patients From China: Ethnic-Related Mutations In Brca1 Associated With An Increased Risk Of Ovarian Cancer

Brca1 And Brca2 Mutations In Ovarian Cancer Patients From China: Association Of Ethnic-Specific Mutations In Brca1 With An Increased Risk Of Ovarian Cancer

Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer

Comprehensive Analysis of Regulatory Factors and Immune-Associated Patterns to Decipher Common and BRCA1/2 Mutation-Type-Specific Critical Regulation in Breast Cancer

Roles of BRCA1 and Its Interacting Proteins.

BRCA1 and BRCA2 Gene Mutations of Familial Breast Cancer and Early-Onset Breast Cancer from Hunan Province in China

Clinical implications for BRCA gene mutation in breast cancer